Introduction {#Sec1}
============

According to the GLOBOCAN 2012 database, 952,000 new cases of gastric cancer and 723,000 cases of gastric cancer-related death are reported worldwide, which correspond to the total malignant cases of 8.5 and 10.1 %, respectively. Lymph node metastasis is known to be one of the most important prognostic factors for gastric cancer. Although the lymph node staging system, based on the extent of lymph node metastasis, was abandoned in the latest guideline of the Japanese Gastric Cancer Association (JGCA) \[[@CR1]\], the prognostic ability of the lymph node staging system of the Union for International Cancer Control (UICC) remains controversial. Some authors indicated that the latest lymph node classification, as part of UICC staging, is influenced by the number of retrieved lymph nodes \[[@CR2]\]. Moreover, certain studies suggested that the ratio-based lymph node system, which evaluates the ratio of metastatic lymph nodes and total retrieved lymph nodes, was theoretically superior to the involved number-based lymph node system, as the former system considers information of both metastatic and the total retrieved lymph nodes \[[@CR3], [@CR4]\]. The favourable results obtained from a comparison of survival with the ratio-based lymph node system suggest that this system may serve as an alternative to the traditional one. However, some studies indicated that patients with the same LNR staging had different survival outcomes, along with changes in the total number of retrieved lymph nodes, particularly when the LNR value was 0 or 1 \[[@CR5]\].

Log odds of positive nodes (LODDS) is a novel, promising lymph node staging system and is defined as the log of the ratio of the number of positive lymph nodes and the total number of retrieved lymph nodes. The LODDS system has a better discrimination ability for patients without metastatic lymph nodes and has been considered as a more reliable method than the pN or LNR systems for prognostic evaluation in gastric cancer patients \[[@CR6], [@CR7]\]. Till now, there is no study to compare the prognostic significance of pN, LNR and LODDS systems together in Asian patients after D2 lymphadenectomy.

In the present study, we aimed to compare the prognostic performance of the pN, LNR and LODDS lymph node staging systems and to determine the most appropriate lymph node staging system for predicting overall survival in gastric cancer patients.

Materials and methods {#Sec2}
=====================

Patients and surveillance {#Sec3}
-------------------------

Between January 1994 and December 2008, all the cases diagnosed with gastric adenocarcinoma after radical surgery in the Department of Gastrointestinal Surgery of the First Affiliated Hospital, Sun Yat-sen University, China, were retrospectively analysed. The eligibility criteria were as follows: patients with gastric adenocarcinoma diagnosed via a histopathologic examination; patients receiving R0 resection and D2 lymphadenectomy, or extensive lymphadenectomy if necessary; patient death due to cancer and patients with complete follow-up data. The exclusion criteria were as follows: patients with a history of malignant tumours at other sites or gastric stump cancer. patients who were diagnosed with distant metastasis preoperatively or during the operation, patients who received neoadjuvant chemotherapy or radiochemotherapy and patients who died due to postoperative complications. In total, 935 patients were included in this study.

Written informed consent was obtained from all the patients preoperatively. The study was approved by the Ethics Committees of The First Affiliated Hospital of Sun Yat-sen University.

All the cases were followed up every 3 months in the first 2 years, every half year in the after 3 years and every year thereafter. Follow-up program consisted of physical examination, serum tumour markers, chest X-ray, annual gastroscope, abdominal CT scan or ultrasound every 6 months. The last follow-up was in December 2014. The median follow-up time was 56 months.

Lymph node classifications {#Sec4}
--------------------------

Lymph nodes were classified according to the seventh edition of the UICC/AJCC tumour-node-metastasis (TNM) system, based on the number of metastatic lymph nodes: N0, negative; N1, 1--2 positive lymph nodes; N2, 3--6 positive lymph nodes; N3, \>6 positive lymph nodes. The LNR was defined as the ratio between the metastatic lymph nodes and total retrieved lymph nodes. The LNR ranged from 0 to 1 and was stratified at intervals of 0.1; it was used to compare the overall survival among each interval and among adjacent subgroups with similar survival outcomes. The LNR system was classified as follows: LNR0, 0; 0.01 \< LNR1 ≤ 0.1; 0.1 \< LNR2 ≤ 0.25 and LNR3 \> 0.25. LODDS was defined as log (\[pLN + 0.5\] / \[nLN + 0.5\]), where pLN is the number of positive lymph nodes and nLN is the number of negative lymph nodes; 0.5 was added to both the numerator and denomination to avoid singularity. A similar method was performed to stratify LODDS, with an interval of 0.5. Thus, LODDS was classified as follows: LODDS1 ≤ −1.5, −1.5 \< LODDS2 ≤ −1.0, −1.0 \< LODDS3 ≤ 0.0 and LODDS4 \> 0.0.

Statistical analysis {#Sec5}
--------------------

The overall survival rate was calculated according to the life table method, and the log-rank test was used to assess statistical differences between groups. Survival curves were established using the Kaplan-Meier method. All the parameters that were statistically significant in the univariate analysis were included in the multivariate Cox proportional hazard model. With the Cox proportional hazard model, the likelihood ratio (*χ* ^2^) test was used to measure homogeneity between groups, whereas the Akaike information criterion (AIC) was adopted to minimise any potential bias when comparing different prognostic systems. The AIC was defined by a −2 log maximum likelihood +2, multiplied by the number of parameters in the model. The discriminatory ability and monotonicity of gradients were measured using the linear trend *χ* ^2^ test. The accuracy of the prognostic evaluation of different staging systems was compared using receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC). The accepted level of statistical significance was defined as *P* \< 0.05. The statistical analysis was performed using the SPSS 18.0 statistical package (SPSS Inc., Chicago, IL).

Results {#Sec6}
=======

Clinicopathological characteristics and survival analysis {#Sec7}
---------------------------------------------------------

In total, 935 patients were enrolled, including 636 men and 299 women, with a mean age of 57.5 years (range, 24--87 years). The gastric cancer was located in the lower part of the stomach (44.7 %) in most cases, followed by the upper portion (31.6 %), middle portion (21.7 %) and the entire stomach (2.0 %). Moreover, the average number of total retrieved lymph nodes was 24.9 per case (range, 0--140). The mean number of involved lymph nodes in our cohort was 4.61 (range, 0--124). Among 18.6 % of the patients, lymph node retrieval was insufficient. The 5-year survival rate of our cohort was 54.0 %, with a median overall survival time of 53.3 months (range, 1.3--148.4 months). Table [1](#Tab1){ref-type="table"} shows the demographics and survival results of our study.Table 1Clinicopathological characteristics and survival analysis of 935 patients with gastric cancer following radical gastrectomyVariablePatients (%)5-year survival rate*χ* ^2^ value (log-rank test)*P* valueAge (years)7.67670.006 \<60526 (56.3 %)57.2 % ≧60409 (43.7 %)49.9 %Sex3.1900.074 Male636 (68.0 %)52.0 % Female299 (32.0 %)58.2 %Tumour site30.575\<0.001 Upper295 (31.6 %)43.1 % Middle203 (21.7 %)60.1 % Lower418 (44.7 %)60.0 % Whole19 (2.0 %)26.3 %Tumour size79.694\<0.001 \<5 cm613 (65.6 %)63.4 % ≧5 cm322 (34.4 %)36.0 %Gross type69.323\<0.001 Borrmann I + II351 (37.5 %)71.5 % Borrmann III + IV584 (62.5 %)43.4 %Degree of differentiation12.898\<0.001 Well/moderately340 (36.4 %)61.1 % Pooly/undifferentiated595 (63.6 %)50.0 %Seventh T stage (UICC)159.378\<0.001 T~1~162 (17.3 %)86.4 % T~2~125 (13.4 %)74.3 % T~3~330 (35.3 %)52.4 % T~4~318 (34.0 %)31.1 %Seventh N stage (UICC)281.440\<0.001 N0364 (38.9 %)81.6 % N1172 (18.4 %)56.4 % N2199 (21.3 %)40.2 % N3200 (21.4 %)18.0 %LNR stage368.726\<0.001 LNR0364 (38.9 %)81.6 % LNR1143 (15.3 %)63.6 % LNR2197 (21.1 %)42.6 % LNR3231 (24.7 %)14.3 %LODDS stage428.720\<0.001 LODDS1277 (29.6 %)87.0 % LODDS2170 (18.2 %)65.9 % LODDS3385 (41.2 %)37.7 % LODDS4103 (11.0 %)7.0 %Number of LN retrieved16.801\<0.001 \<15174 (18.6 %)42.0 % ≧15761 (81.4 %)56.7 %

Survival impact of pN, R stage and LODDS {#Sec8}
----------------------------------------

The survival curves of patients according to pN, LNR and LODDS were all significantly different (Fig. [1a--c](#Fig1){ref-type="fig"}) (all, *P* \< 0.001). In the univariate analysis, age, tumour location, tumour size, gross type, histological type, number of retrieved lymph nodes, pN, LNR and LODDS were significantly correlated with overall survival (Table [2](#Tab2){ref-type="table"}). All the potential prognostic factors identified in the univariate analysis were included in the multivariate analysis. All the three lymph node staging systems (pN, LNR and LODDS) were identified as significantly independent prognostic factors of overall survival in our cohort (Table [3](#Tab3){ref-type="table"}).Fig. 1Kaplan-Meier analysis of overall survival (OS) for cases with gastric cancer according to different lymph node staging systems: **a** survival curves of patients according to the pN system, **b** survival curves of patients according to the LNR system and **c** survival curves of patients according to the LODDS system Table 2Univariate analysis of overall survival in gastric cancerParameters*χ* ^2^ valueHazard ratio95 % CI^a^*P* valueAge7.6191.2931.077--1.5510.006Gender3.1830.074Tumour location29.540\<0.001 Upper Middle12.3930.6320.489--0.816\<0.001 Lower17.2460.6450.525--0.794\<0.001 Whole3.4801.6790.974--2.8940.062Tumour size75.3772.2511.874--2.703\<0.001Gross type65.0282.3931.936--2.959\<0.001Histological type12.7351.4301.175--1.741\<0.001T stage134.757\<0.001 T~1~ T~2~4.7731.7161.057--2.7870.029 T~3~42.4843.6452.470--5.377\<0.001 T~4~91.6556.4494.403--9.446\<0.001Insufficient retrieved lymph nodes16.4840.6370.512--0.792\<0.001pN101.762\<0.001 pN~0~ (reference) pN~1~11.4131.7161.254--2.3470.001 pN~2~37.0782.4611.842--3.289\<0.001 pN~3~94.8074.2553.161--5.648\<0.001rN191.740\<0.001 rN~0~ (reference) rN~1~20.9622.4071.653--3.506\<0.001 rN~2~70.5924.0502.922--5.612\<0.001 rN~3~174.15112.7568.739--18.618\<0.001LODDS427.771\<0.001 LODDS1 (reference) LODDS227.1662.6971.857--3.917\<0.001 LODDS3123.2865.7774.239--7.874\<0.001 LODDS4272.25519.59413.761--27.900\<0.001*CI* ^a^ confidence interval Table 3Multivariate analysis of overall survival in gastric cancer for the different lymph node staging systemsParametersMultivariate analysis 1Multivariate analysis 2Multivariate analysis 3HR95 % CI^a^*p* ValueHR95 % CI^a^*p* ValueHR95 % CI^a^*P* valueAge1.3691.139--1.6460.0011.4091.171--1.695\<0.0011.3401.1141.6120.002GenderTumour location Upper Middle Lower WholeTumour size1.3201.087--1.6030.0051.2571.034--1.5270.021Gross type1.2921.024--1.6300.0311.3461.069--1.6850.01213451.073--1.6860.010Histological typeT stage\<0.001 T~1~ (reference) T~2~1.0930.664--1.7990.7281.0700.648--1.7650.7921.0290.625--1.6930.911 T~3~1.7611.150--2.6940.0091.7221.127--2.6330.0121.8181.197--2.7590.005 T~4~2.2241.440--3.433\<0.0012.1731.409--3.350\<0.0012.3631.550--3.603\<0.001Insufficient retrieved lymph nodes0.4880.389--0.612\<0.0010.6220.499--0.776\<0.0010.7480.597--0.938\<0.001pN\<0.001 pN~0~ (reference) pN~1~1.6971.241--2.3200.001 pN~2~2.6101.951--3.491\<0.001 pN~3~4.9873.704--6.714\<0.001rN\<0.001 rN~0~ (reference) rN~1~1.6171.142--2.290.007 rN~2~2.4861.843--3.353\<0.001 rN~3~5.7024.280--7.596\<0.001LODDS\<0.001 LODDS1 (reference) LODDS22.1441.457--3.153\<0.001 LODDS33.8402.765--5.333\<0.001 LODDS412.0358.234--17.590\<0.001*CI* ^a^ confidence interval

Comparison of prognostic ability among pN, R stage and LODDS {#Sec9}
------------------------------------------------------------

To identify the most appropriate system of representing lymph node involvement for the evaluation of overall survival in gastric cancer patients, we adopted the linear trend *χ* ^2^ score to evaluate the discriminatory ability and monotonicity of gradients, the likelihood ratio (*χ* ^2^) test to assess homogeneity ability and AIC value and ROC curve to compare the prognostic ability among the systems. We observed that LODDS had the highest linear trend *χ* ^2^ score and likelihood ratio (*χ* ^2^) test score, lowest AIC value and largest AUC (Table [4](#Tab4){ref-type="table"}). Therefore, we considered that the LODDS was superior to LNR and pN.Table 4Prognostic ability comparison among the different lymph node staging systems for gastric cancerLinear trend *χ* ^2^ scoreLikelihood ratio *χ* ^2^ testAIC valueROC areaSeventh UICC pN215.021280.8265769.0370.767rN262.177367.9085706.2940.793LODDS266.743427.7715670.2260.793

To elucidate the reason for the superiority of LODDS compared to pN and LNR, we created scatter plots of the relationship between LODDS and the number or ratio of lymph node involvement. As shown in Fig. [2a, b](#Fig2){ref-type="fig"}, the LODDS value increased with the number and the ratio of metastatic lymph nodes, indicating close relationships between LODDS and pN, as well as LNR. However, these correlations were not linear. When the number of lymph nodes involved was ≤10 or when the ratio of lymph node metastasis was \<0.2, the curves of pN and LNR increased at a slower rate as compared to the LODDS, indicating that LODDS could be superior to pN and LNR in the prediction of long-term overall survival of the cases mentioned above. Moreover, when the ratio of lymph node metastasis was 0 or 1, the LODDS score was heterogeneous, indicating that the LODDS system had the potential to indicate different survival outcomes for patients with the same LNR stage, especially for cases with an LNR score of 0 or 1.Fig. 2Scatter plots of the relationship between LODDS and the number or ratio of lymph nodes involved: **a** scatter plots of the relationship between LODDS and the number of metastatic lymph nodes and **b** scatter plots of the relationship between LODDS and LNR

Correlation among the total number of retrieved lymph nodes, pN, LNR and LODDS {#Sec10}
------------------------------------------------------------------------------

A Pearson test was conducted to evaluate the correlation of the total number of retrieved lymph nodes with the pN, LNR and LODDS systems. A strong relationship was observed between the total number of retrieved lymph nodes and the number or ratio of metastatic lymph nodes (*r* = 0.214 and 0.077, *P* \< 0.001 and 0.018, respectively). However, there was no association between the number of retrieved lymph nodes and LODDS (*r* = −0.038, *P* = 0.251). The results of Pearson analysis indicated that LODDS was positively correlated with pN and LNR (*r* = 0.868 and 0.888, *P* \< 0.001 and \<0.001, respectively), whereas a strong relationship was present between pN and LNR (*r* = 0.938, *P* \< 0.001).

Evaluation of the prognostic value of different lymph node staging systems with different levels of retrieved lymph nodes {#Sec11}
-------------------------------------------------------------------------------------------------------------------------

To assess the prognostic abilities of pN, LNR and LODDS with different levels of retrieved lymph nodes, all the patients were divided into four groups according to the number of retrieved lymph nodes: group 1 (≤10, *n* = 93), group 2 (11--14, *n* = 81), group 3 (15--25, *n* = 405) and group 4 (\>25, *n* = 356). As shown in Table [5](#Tab5){ref-type="table"}, pN, LNR and LODDS showed prognostic stratification abilities among the different subgroups. We further compared the prognostic performance among the groups. We noted that in all four groups, the LODDS system had the highest linear trend *χ* ^2^ score, likelihood ratio (*χ* ^2^) test score and lowest AIC value, followed by the LNR system and pN system. Similarly, the LODDS system had the largest AUC in group 1 and group 3. However, in group 2 and group 4, the LNR system had the largest AUC, followed by the LODDS and pN systems (Table [6](#Tab6){ref-type="table"}).Table 5Evaluation of the prognostic value of the different lymph node systems with different levels of retrieved lymph nodesNumber5-year survival rate*χ* ^2^ value*P* valueRetrieved LN (≦10)93Seventh UICC pN staging9.7920.020 pN~0~47 (50.5 %)61.7 % pN~1~25 (26.9 %)40.0 % pN~2~18 (19.4 %)33.3 % pN~3~3 (3.2 %)0.0 %pN ratio39.029\<0.001 rN~0~47 (50.5 %)74.5 % rN~1~5 (5.4 %)40.0 % rN~2~15 (16.1 %)33.3 % rN~3~26 (28.0 %)11.5 %LODDS64.853\<0.001 LODDS14 (4.3 %)100.0 % LODDS242 (45.2 %)73.8 % LODDS335 (37.6 %)28.6 % LODDS412 (12.9 %)0.0 %Retrieved LN (11--14)81Seventh UICC pN staging33.848\<0.001 pN~0~34 (42.0 %)91.2 % pN~1~18 (22.2 %)27.8 % pN~2~16 (19.8 %)25.0 % pN~3~13 (16.0 %)23.1 %pN ratio61.503\<0.001 rN~0~34 (42.0 %)91.2 % rN~1~9 (11.1 %)55.6 % rN~2~18 (22.2 %)33.3 % rN~3~20 (24.7 %)5.0 %LODDS66.012\<0.001 LODDS13 (3.7 %)100.0 % LODDS231 (38.3 %)90.3 % LODDS334 (42.0 %)35.3 % LODDS413 (16.0 %)0.0 %Retrieved LN (15--25)405Seventh UICC pN staging101.302\<0.001 pN~0~164 (40.5 %)79.9 % pN~1~77 (40.5 %)57.1 % pN~2~104 (25.7 %)41.3 % pN~3~60 (14.8 %)18.3 %pN ratio117.273\<0.001 rN~0~164 (40.5 %)79.9 % rN~1~62 (15.3 %)61.3 % rN~2~96 (23.7 %)47.9 % rN~3~83 (20.5 %)16.9 %LODDS135.377\<0.001 LODDS1147 (36.3 %)85.7 % LODDS248 (11.9 %)52.1 % LODDS3175 (43.2 %)42.3 % LODDS435 (8.6 %)11.4 %Retrieved LN (\>25)356Seventh UICC pN staging150.634\<0.001 pN~0~119 (33.4 %)84.0 % pN~1~53 (14.9 %)71.6 % pN~2~60 (16.9 %)46.7 % pN~3~124 (34.8 %)17.7 %pN ratio160.727\<0.001 rN~0~119 (33.4 %)84.0 % rN~1~69 (19.4 %)68.1 % rN~2~67 (18.8 %)40.3 % rN~3~101 (28.4 %)13.9 %LODDS173.033\<0.001 LODDS1123 (34.6 %)87.8 % LODDS249 (13.8 %)57.1 % LODDS3141 (39.6 %)34.8 % LODDS443 (12.1 %)7.0 % Table 6Comparison of prognostic value of the different pN staging systems with different levels of retrieved lymph nodes for gastric cancerLinear trend *χ* ^2^ scoreLikelihood ratio *χ* ^2^ testAIC valueROC areaRetrieved LN (≦10) Seventh UICC pN9.5779.776410.0230.669 rN28.11338.959384.1980.792 LODDS29.65764.653370.8190.804Retrieved LN (11--14) Seventh UICC pN24.72033.769306.7130.829 rN39.79561.343292.0890.889 LODDS49.66165.832290.8300.877Retrieved LN (15--25) Seventh UICC pN80.198101.1102109.7850.747 rN88.779117.0452099.3590.760 LODDS95.421135.1262082.6450.763Retrieved LN (\>25) Seventh UICC pN111.970150.2291851.2480.809 rN113.450160.3001848.6280.813 LODDS114.897172.5731840.3840.810

Survival analysis of the pN and LNR subgroups according to the LODDS stratification {#Sec12}
-----------------------------------------------------------------------------------

To evaluate the survival impact of the LODDS stratification as per the pN and LNR systems, all the distinct prognostic cohorts stratified according to the pN or LNR systems were analysed based on different LODDS stratifications. We observed that the LODDS could discriminate among N0, N1, N2 and N3, regardless of whether the pN or LNR system was used, suggesting that LODDS had excellent prognostic discriminatory ability to assess the current lymph node system. All the survival data and statistical results were shown in Table [7](#Tab7){ref-type="table"}.Table 7Survival analysis of pN stage and rN systems according to the LODDS staging systemNumber5-year survival rate*χ* ^2^ value*P* valueUICC pNUICC pN~0~22.895\<0.001 LODDS1267 (73.4 %)89.9 % LODDS297 (26.6 %)67.0 %UICC pN~1~28.892\<0.001 LODDS110 (5.8 %)90.0 % LODDS268 (39.3 %)64.7 % LODDS394 (54.3 %)46.8 % LODDS41 (0.6 %)0.0 %UICC pN~2~11.0040.004 LODDS26 (3.0 %)83.3 % LODDS3184 (92.9 %)40.2 % LODDS48 (4.1 %)12.5 %UICC pN~3~17.658\<0.001 LODDS3106 (53.0 %)26.8 % LODDS494 (47.0 %)9.6 %rNrN~0~22.895\<0.001 LODDS1267 (73.4 %)89.9 % LODDS297 (26.6 %)67.0 %rN~1~9.2650.010 LODDS110 (6.8 %)90.0 % LODDS274 (50.7 %)69.2 % LODDS362 (42.5 %)50.4 %rN~2~6.3660.012 LODDS219 (9.7 %)73.7 % LODDS3177 (90.3 %)40.1 %rN~3~22.961\<0.001 LODDS3126 (55.0 %)17.6 % LODDS4103 (45.0 %)9.7 %

Discussion {#Sec13}
==========

Information on lymph node involvement in gastric cancer has a great clinical impact on treatment decisions and survival assessment. The number-based lymph node staging system of UICC classification (seventh edition) was widely used, although a principle flaw is that the prognostic accuracy is influenced by the number of total retrieved lymph nodes \[[@CR8], [@CR9]\]. The most recent NCCN guideline recommends that D2 lymphadenectomy should be used to remove an adequate number of lymph nodes (no less than 15); however, some studies reported that ≥15 lymph nodes are harvested in only 29 and 60.2 % of cases in the USA \[[@CR10]\] and China \[[@CR11]\]. Moreover, the optimal number of retrieved lymph nodes to avoid stage migration remains unclear in some studies \[[@CR12], [@CR13]\]. Hence, in cases where the number of tested lymph nodes was insufficient, the staging migration phenomenon may occur.

The LNR system considers both the information of nodal involvement and total lymph nodes tested and can theoretically overcome the limitations of number-based nodal system. Most authors indicated that LNR was superior to the pN system due to the presence of a larger power for minimising staging migration \[[@CR14]\]. A recent large cohort study (nearly 9000 cases) on gastric cancer in Korea \[[@CR15]\] concluded that the LNR system is a better alternative for predicting long-term survival and compensating for the stage migration effect. However, due to some limitations, it cannot be considered as an alternative to the current pN staging. First, there is no difference among the patients with negative lymph nodes between the pN and LNR systems, indicating that LNR does not have the ability to distinguish the difference in survival in pN0 patients. Moreover, the cut-off value of LNR reported in several studies is varied \[[@CR14], [@CR16], [@CR17]\]. In addition, the patients in the same LNR stage may have different survival outcomes, with a different number of tested lymph nodes \[[@CR18]\].

LODDS---a novel system for assessing the status of lymph node involvement---is an alternative option for the evaluation of metastatic lymph nodes to predict overall survival; however, this system has only been investigated in cases of colon cancer and breast cancer. Following the report of Sun \[[@CR6]\] who emphasised the favourable prognostic impact of LODDS in gastric cancer, some studies in China and North America have validated its use for prognostic purposes. Another study \[[@CR11]\] proposed a new tumour-LODDS-metastasis (TLM) classification, which was based on the LODDS system, and was superior to the TNM and tumour-ratio-metastasis (TRM) classifications in the prognostic assessment of cases following D2 lymphadenectomy. Some studies did not note any superiority of LODDS over the pN or LNR systems \[[@CR10], [@CR19]\]. Yu \[[@CR20]\] indicated the LODDS system may reflect a false survival outcome for patients with gastric cancer, with a reduced true hazard ratio of the N status against survival. An ideal lymph node staging system should satisfy three conditions \[[@CR21]\]: decreased patient survival with increasing stage (monotonicity), similar survival within a group (homogeneity) and difference in survival between groups (distinctiveness). To our knowledge, the present study is the first to compare the above three conditions among the pN, LNR and LODDS systems. In multivariate Cox regression analysis in the present study, the pN, LNR and LODDS systems were all found to be independent parameters for overall survival. Moreover, the LODDS system had the highest linear trend *χ* ^2^ score, likelihood ratio (*χ* ^2^) test score, largest AUC and lowest AIC value, indicating that the LODDS system was superior to both the pN system and LNR system.

Theoretically, the LODDS system was superior to the pN system in minimising stage migration, particularly in cases where the number of analysed lymph nodes was insufficient \[[@CR22]\]. We further interpret that this novel system had a remarkable robustness in terms of the prognostic effect and discrimination ability at different levels of tested lymph nodes. As shown in Table [5](#Tab5){ref-type="table"}, when the number of retrieved lymph nodes was insufficient (≤10 or 11--14), the LODDS system had the best performance in homogeneity, discriminatory ability, monotonicity of gradients and accuracy of the prognosis evaluation, followed by the LNR system and pN system. Moreover, in the present study, the pN and LNR systems were positively correlated with the number of retrieved lymph nodes. However, unlike that reported in the study of Qiu \[[@CR11]\], we found that there was no relationship between the number of tested lymph nodes and the LODDS system, indicating that the LNR and pN systems were affected by the total number of tested lymph nodes, whereas the LODDS system was unaffected. Moreover, Aurello \[[@CR23]\] reported that the LODDS system was a function of the number of negative lymph nodes, whereas the LNR system was a function of the number of total retrieved lymph nodes; hence, theoretically, the LODDS system was superior to the LNR system. Jiao \[[@CR24]\] explained that cases with an increasing number of tested lymph nodes may reflect better survival, particularly in patients with node-negative gastric cancer. For patients with an LNR value 0 or 1, the LNR system had no discriminatory power. As shown in Fig. [2b](#Fig2){ref-type="fig"}, the LODDS system can distinguish patients with an LNR value 0 or 1, which accounted for 39.6 % of the total number of patients. Moreover, using the log-rank test, we noted that LODDS had the ability to distinguish between patients with different pN or LNR systems into distinct prognostic groups. This evidence strongly suggests that the LODDS system may be the most reliable method for lymph node classification in gastric cancer.

Our study had certain limitations. First, all data was obtained from a single institution, and this may not reflect the status in other centres in China. Moreover, the method of calculation in the LODDS system was complicated, which may limit the clinical application of the LODDS system.

In conclusion, the pN, LNR and LODDS systems appear to be independent prognostic factors, as determined by the multivariate analysis. Although the LODDS system was more complex, it showed prognostic superiority over both the pN and LNR systems in our study. It can discriminate survival differences of gastric cancer patients with negative lymph nodes and an insufficient number of retrieved lymph nodes. Hence, the LODDS system should be considered as a novel and promising lymph node staging system for gastric cancer in the future.
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